Valeant Pharmaceuticals International Inc. surprised investors Tuesday and maintained its full-year guidance, setting a goal for the second half that will require the drugmaker to substantially raise its sales and profits.
As part of a planned turnaround, Valeant plans to sell assets that the company thinks will be worth about $8 billion, will renegotiate terms with lenders and will reorganize its business into three main segments as it tries to stabilize sales of several important but struggling products.
11:10 Merged BAT-Reynolds could be loaded with up to $55 billion of debt, analysts say6
12:45 Oasis Petroleum offers stock to raise funds for Bakken purchase
16:51 Scottrade Sale Nearly Doubles Owner’s Wealth to $4 Billion10
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner7